12:00 AM
 | 
Nov 16, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Carfilzomib: Additional Phase II data

Additional data from 51 evaluable Velcade bortezomib-naïve patients in the ongoing, open-label, North American Phase II PX-171-004 trial showed that 20 mg/m 2 IV carfilzomib produced an overall response rate of 45%, including 1 complete response, 4 very good partial responses and 18 partial responses....

Read the full 213 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >